Desensitization With Bortezomib Before a Living Kidney Donation
NCT ID: NCT01842074
Last Updated: 2016-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
10 participants
INTERVENTIONAL
2013-03-31
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bortezomib in Rejection of Kidney Transplants
NCT02201576
Desensitization in Kidney Transplantation
NCT00908583
Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
NCT01873157
Carfilzomib and Belatacept for Desensitization
NCT05017545
Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
NCT00261547
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bortezomib
Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
Bortezomib
Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bortezomib
Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* awaiting a living kidney donation
* but with a least one DSA titer between 1000 MFI and 3000 MFI
Exclusion Criteria
* DSA level above 3000 MFI
* and every condition that is a contre indication for bortezomib treatment
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hélène François, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique Hôpitaux de Paris - Bicêtre Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital
Le Kremlin-Bicêtre, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-001988-78
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
P110147
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.